APOBECs and Virus Restriction 2024
A special issue of Viruses (ISSN 1999-4915). This special issue belongs to the section "Human Virology and Viral Diseases".
Deadline for manuscript submissions: 1 December 2024 | Viewed by 313
Special Issue Editor
Interests: APOBECs; cytidine deaminase; AID; viral antagonists; viral hypermutation; innate immunity; viral selection
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
The apolipoprotein B mRNA-editing enzymes, the catalytic polypeptide (APOBEC) family of enzymes, are responsible for the deamination of cytosine in single-stranded RNA and DNA. In humans, this family includes 11 members, including APOBEC1, 2, 3A, 3B, 3C, 3D, 3F, 3G, 3H, 4, and activation-induced cytidine deaminase (AID). The functions of these enzymes range from the epigenetic modifications of DNA, including the removal of methylcytosine and 5-hydroxymethylcytosine, to the mutagenesis of host and viral mRNAs. Current evidence suggests that both RNA and DNA viruses are mutagenized by APOBECs, leading to selection and altered pathogenicity. Although APOBECs are typically associated with the innate immune response to viral infections, AID is a primordial member of the family that controls the affinity maturation of antibodies as well as effector functions via class switch recombination. The viral manipulation of APOBECs is often observed in enzyme relocalization or degradation, and APOBEC antagonists include both virally specified RNAs and proteins. This Special Issue will address new insights into APOBEC inhibitors and their impact on viral selection as well as the immune response.
Prof. Dr. Jaquelin P. Dudley
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Viruses is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cytosine deamination
- methylcytosine
- epigenetics
- mutagenesis
- cancer
- APOBEC antagonists
- innate immunity
- adaptive immunity
- virus selection
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
